ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 25

Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort

Angela Cesta1, Xiuying Li1, Mark Tatangelo2,3 and Claire Bombardier1,4,5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Clinical Decision Making and Health Care, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: health behaviors, outcomes, patient engagement, patient participation and registry

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The generalizability and validity of in longitudinal observational studies is contingent on participant characteristics. If attrition is not random, it is important to identify any systematic differences b etween patients who continue to participate versus those who drop out. The purpose of this analysis was to compare characteristics of rheumatoid arthritis (RA) patients who continue to participate in the Ontario Best Practices Research Initiative (OBRI) to those of patients who have dropped out prior to reaching their 3 yr follow up.

Methods: Currently, 61 rheumatologists in Ontario (51% of active rheumatologists in Ontario) recruit patients into the OBRI. As of January 2015, 1533 patients had consented and were eligible to participate. 175 (11.4%) patients dropped out before reaching their 3 yr follow up assessment. Among the drop outs, 109 (7.1%) withdrew consent, 38 (2.5%) were lost to follow up, and 28 (1.8%) refused to re-consent after 2 yrs of follow up. In addition to the drop outs, 38 (2.5%) patients had died. 1320 (86.1%) patients remained active participants. Patient characteristics and disease activity at enrollment were compared in the 175 patients who dropped out versus the 1320 patients who continued to participate. A survival curve was generated to look at time of drop out over the 3 year follow up period.

Results: Patients who dropped out were similar to those who remained active with respect to age, gender, race, education, employment status, having private insurance, disease duration, number of comorbidities, and living alone. Compared to patients who dropped out, patients who continued to participate had higher household incomes, lower disease activity scores, and were more likely to be taking a biologic at the time of enrollment (Table 1). The survival curve shows that the majority of patients drop out within the first two years (Figure 1).

Conclusion: Patients with higher disease activity at enrollment were more likely to drop out. The OBRI attrition rate was 11.4% during the first three years of follow up, with 4.7% of patients dropping out in the first year, 3.5% in the second year and 3.2% in the third year. OBRI attrition rates were lower than those reported in the BRASS cohort (4.31% per 6 month follow up cycle) 1 and the ARAMIS cohort (6% per year) 2. The lower number of drop outs in the OBRI cohort could be attributed to the time invested in rheumatologist site visits by our study monitors and the biannual follow-up by our OBRI telephone interviewers.

Reference:

1. Iannaccone et al., Arthritis Care &Research, Jul 2013

2. Reisine et al., ACR, Feb 2000

Table 1: Patient Characteristics and Disease Activity at Time of Enrollment into OBRI

Patients who Dropped Out

(N = 175)

Active Patients

(N = 1320)

Age, Mean (SD)

57.1 (15.4)

56.9 (12.6)

Female, N (%)

125 (75%)

1041 (79%)

White, N (%)

140 (88%)

1133 (91%)

Education, N (%)

Less than High School

High School

College or greater

21 (13%)

106 (8%)

65 (39%)

492 (38%)

81 (49%)

699 (54%)

*Household Income, N (%)

<20,000

20,000-34,999

35,000-49,999

50,000-74,999

³75,000

Missing data

15 (9%)

98 (7%)

22 (13%)

147 (11%)

18 (10%)

153 (12%)

19 (11%)

171 (13%)

29 (17%)

344 (26%)

72 (41%)

407 (31%)

Live Alone, N (%)

28 (17%)

178 (14%)

Employment (Full time), N (%)

75 (45%)

615 (52%)

Having Private Insurance, N (%)

101 (60%)

848 (68%)

Duration of Disease (yrs), Mean (SD)

7.8 (9.9)

9.2 (9.8)

*DAS28 (0-9.4), Mean (SD)

4.9 (4.4)

4.4 (1.6)

*CDAI (0-76), Mean (SD)

25.7 (14.7)

20.9 (14.3)

*HAQ (0-3), Mean (SD)

1.44 (0.78)

1.22 (0.76)

*Pain Score (0-3), Mean (SD)

1.76 (0.89)

1.48 (0.87)

*RADAI (0-10), Mean (SD)

4.8 (2.2)

4.0 (2.2)

Number of Co-morbidities, Mean (SD)

2.3 (1.9)

2.5 (2.1)

*RA Medications

Biologic monotherapy, N (%)

Biologic combination therapy, N (%)

7 (4%)

68 (5%)

6 (4%)

132 (10%)

*P²0.05


Disclosure: A. Cesta, None; X. Li, None; M. Tatangelo, None; C. Bombardier, None.

To cite this abstract in AMA style:

Cesta A, Li X, Tatangelo M, Bombardier C. Attrition and Participant Characteristics in a Rheumatoid Arthritis Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/attrition-and-participant-characteristics-in-a-rheumatoid-arthritis-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/attrition-and-participant-characteristics-in-a-rheumatoid-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology